Dr. Hyman L. Kirschenbaum, MD

Dr. Kirschenbaum practices at The Malo Clinic Center for Ambulatory Surgery LLC in Rutherford, New Jersey.

Dr. Kirschenbaum's NPI, 1063405900, was assigned on August 25, 2005. Dr. Kirschenbaum graduated from New York Medical College in 1977. Dr. Kirschenbaum holds New Jersey license 25MA04025600.

Dr. Kirschenbaum's primary practice is The Malo Clinic Center for Ambulatory Surgery LLC, at 201 State Highway 17, Rutherford, NJ 07070 in Bergen County. The practice phone is (201) 549-8890.

Dr. Kirschenbaum's primary practice is The Malo Clinic Center for Ambulatory Surgery LLC in Rutherford, New Jersey. Dr. Kirschenbaum is also affiliated with Hackensack University Medical Center. The medical group on file is Optum Medical Care New Jersey. Dmand AI also links Dr. Kirschenbaum to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kirschenbaum practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Kirschenbaum's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Kirschenbaum's licenses on file in 2 states: New Jersey and New York.

CMS data shows 91 Medicare services from Dr. Kirschenbaum across 3 procedure codes in 2024, all of them office visits, for 60 Medicare patients. Medicare paid $9,127 for them. Every service was in an office.

CMS counts 60 Medicare patients who saw Dr. Kirschenbaum in 2024. The largest group is 65 to 74, with 30 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 53% are also on Medicaid. Their average risk score is 1.09, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kirschenbaum's median patient age at 54, with 53% women.

In 2024, Dr. Kirschenbaum wrote 685 Medicare Part D claims for 216 patients. 87% of them were for generic drugs. CMS names the drug for 597 of them, across 12 drugs with 11 or more claims each, at $10,164 in total drug cost. In 2023, CMS named 492 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Kirschenbaum for performance year 2024, reported as part of a group. Dr. Kirschenbaum accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kirschenbaum as offering telehealth.

CMS Open Payments shows 136 general payments to Dr. Kirschenbaum from 21 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Gilead Sciences, Inc. paid the most, $978.

Dr. Kirschenbaum graduated from New York Medical College in 1977.